you can read the #expert_review_of_over #350articles on the #medical_safety_profile_of_ivermectin

Ivermectin in COVID-19 These pages contain the scientific rationale that justifies the use of ivermectin in COVID-19. We regard ivermectin as a core medication in the prevention and treatment of COVID-19. For comprehensive information on ivermectin please refer to our Review of the Emerging Evidence Supporting the Use of Ivermectin in the Prophylaxis and Treatment of COVID-19 and the included references. For questions about the safety of this medicine, you can read the expert review of over 350 articles on the medical safety profile of ivermectin that was conducted by a toxicologist for Medincell, which reported that “No safety concern was anticipated that would prevent health authorities from assessing the use of Ivermectin against COVID-19.” The review is available at www.medincell.com/ivermectin A more recent paper, Meta-analysis of Randomized Trials of Ivermectin to treat SARS-CoV-2 Infection was accepted for publication July 6, 2021, by Oxford University Press on behalf of the Infectious Diseases Society of America. This study was done by Dr. Andrew Hill and the team that researched ivermectin’s efficacy in COVID-19 treatment for the WHO. The data is overwhelmingly positive and was discussed in detail by Dr. Pierre Kory on the FLCCC’s July 7, 2021, Weekly Update. Another recent paper, Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines was published online June 17, 2021, by the American Journal of Therapeutics. It concludes, “Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.” For PATIENTS AND RELATIVES, please review our GUIDE FOR YOU. It tells how to find physicians who prescribe ivermectin as well as provides information to share with your primary care physician in the event that he or she is not aware of the current evidence detailing how safe and effective ivermectin is in preventing and treating all stages of COVID-19 and all variants of the SARS-CoV-2 virus. Ivermectin is a well-known, FDA-approved anti-parasite drug that has been used successfully for more than four decades to treat onchocerciasis “river blindness” and other parasitic diseases. It is one of the safest drugs known. It is on the WHO’s list of essential medicines, has been given 3.7 billion times around the globe, and has won the Nobel prize for its global and historic impacts in eradicating endemic parasitic infections in many parts of the world. Our medical discovery of a rapidly growing published medical evidence base, demonstrating ivermectin’s unique and highly potent ability to inhibit SARS-CoV-2 replication and to suppress inflammation, prompted our team to use ivermectin for prevention and treatment in all stages of COVID-19. Ivermectin is not yet FDA-approved for the treatment of COVID-19, but on Jan 14, 2021, the NIH changed their recommendation for the use of ivermectin in COVID-19 from “against” to “neutral”. (see our press release). In March 2020 we created our life-saving MATH+ Hospital Treatment Protocol for COVID-19, which is intended for hospitalized patients. In October 2020 we developed the I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19, which is designed for use as a prophylaxis and in early outpatient treatment, for those who test positive for COVID-19. The protocols complement each other, and both are physiologic-based combination treatment regimens developed by leaders in critical care medicine. All the component medicines are FDA-approved, inexpensive, readily available and have been used for decades with well-established safety profiles. Both protocols are available in several languages.

#Sepsis_敗血症_SuddenDeath_突然死 #Continuous_連続_Cardiac_Output_心拍出量 #noninvasive_Hemodynamis_非侵襲 #メディカルテクニカ #Sepsis_EWS_VitalStream_CaretakerType4 #非侵襲_連続心拍出量_LVET #Labtech #Congenital_Heart_Disease #Labtech #ラブテック社ホルタシステム #ノイマン #Hungary #数学者_コンピュータ_人工知能 #wavelet_decomposition_Alred_Haar #Sepsis_induced_Cardiac_Death_decomposition_wavelet_MedicalTeknika #盛田先生 #現代科学を創った最強の天才 VitalStream #Labtech_Holter #wavelet_algorithm #pedcath8 #Arteriograph24 #Shimmner_Sensing #VitalStream #Labtech_Holter #wavelet_algorithm #メディカルテクニカ #pedcath8 #Arteriograph24 #Shimmner_Sensing #art#マイクロセンサー 世界一 #センサー種類多い 世界最先端 #ディジタル化搭載 #アイルランド製 親会社は米国ボストン Multi #Shimmer Sync for SD Tutorial #動脈硬化指標 #欧州標準特許 #Arteriograph #Tensiomed #PWV #Arterial_Stiffness #Wireless #medicalteknika #ShimmerSensing #マイクロ #電磁センサー #新製品 #非接触 #非侵襲 #12誘導心電図 #銀塩化銀電極不要 #超時間携帯可能 #研究向け #Labtech #ワイヤレス_モバイル_クラウド_カーディオロジ_12誘導心電計 #12誘導心電図伝送を考える会 #12誘導心電図伝送を考える会 #Labteh_wavelet_PwaveAutoDetect_Holter #ラブテック社ホルタシステム #富士山心電図 #Sepsis_敗血症_SuddenDeath_突然死 #Continuous_連続_Cardiac_Output_心拍出量 #noninvasive_Hemodynamis_非侵襲 #先天性心疾患ソフトウエア #Pedcath8 #SSS #PedhMulti #Shimmer Sync for SD Tutorial #Canonが開発 #半導体技術 #大日本印刷 #キオクシア #NeuroMarketing Made Easy - #IVP Research Lab and #Shimmer presentation #ワイヤレス_モバイル_クラウド_カーディオロジ_12誘導心電計 #12誘導心電図伝送を考える会 #Labteh_wavelet_PwaveAutoDetect_Holter #ラブテック社ホルタシステム #Labtech #VitalStream_Caretaker_Medical #Pedcath8 #Cardionics #Arterial_Stiffness #Arteriograph #medicalteknika #参政党 #日本ファースト #マイクロ #電磁センサー #新製品 #非接触 #非侵襲 #12誘導心電図 #銀塩化銀電極不要 #超時間携帯可能 #研究向け #Labtech #ラブテック社ホルタシステム #富士山心電図 #Sepsis_敗血症_SuddenDeath_突然死 #Continuous_連続_Cardiac_Output_心拍出量 #noninvasive_Hemodynamis_非侵襲 #靖国参拝 #参政党・#神谷代表 #日本人として参拝 #政治家は行っちゃダメなの #核武装安上がり論の是非 #ArteriographHolter2 #arteriograph24 #動脈硬化指標 #欧州標準特許 #Arteriograph #Tensiomed #PWV #Arterial_Stiffness #Wireless #medicalteknika #元気カプセル紹介　#vitalstream_caretaker_メディカルテクニカ #VitalStream #Labtech_Holter #wavelet_algorithm #メディカルテクニカ #pedcath8 #Arteriograph24 #Shimmner_Sensing